Recently, the Category 1 innovative product Tegileridine Fumarate Injection (trade name: 艾苏特) of Jiangsu Hengrui Pharmaceuticals Co., Ltd. was approved for marketing by China NMPA. It is indicated for moderate to severe pain after abdominal surgery.

Tegileridine Fumarate Injection is a complete opioid receptor agonists, which has relative selectivity on μ-opioid receptors (MOR) and is subject to the regulation of narcotic drugs. The marketing of this drug provides a new treatment option for patients with moderate to severe pain after abdominal surgery.